Pinnacle Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Pinnacle Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.64M	Sell	21,590 -3,648	-14%	-$1.7M	0.12%	174
2025 Q4	$11.4M	Sell	25,238 -129	-0.5%	-$55.6K	0.15%	148
2025 Q3	$9.93M	Buy	25,367 +259	+1%	+$108K	0.13%	166
2025 Q2	$11.2M	Buy	25,108 +210	+0.8%	+$96.8K	0.16%	143
2025 Q1	$12.1M	Buy	24,898 +12,002	+93%	+$5.59M	0.18%	126
2024 Q4	$5.19M	Buy	12,896 +6,857	+114%	+$3.18M	0.07%	237
2024 Q3	$2.46M	Sell	6,039 -4,822	-44%	-$2.32M	0.04%	333
2024 Q2	$5.09M	Buy	10,861 +1,732	+19%	+$752K	0.08%	242
2024 Q1	$3.82M	Buy	9,129 +3,090	+51%	+$1.31M	0.06%	278
2023 Q4	$2.46M	Buy	6,039 +780	+15%	+$288K	0.04%	337
2023 Q3	$1.83M	Buy	5,259 +1,531	+41%	+$535K	0.03%	364
2023 Q2	$1.31M	Buy	3,728 +1,846	+98%	+$622K	0.02%	428
2023 Q1	$593K	Buy	1,882 +400	+27%	+$120K	0.01%	489
2022 Q4	$428K	Sell	1,482 -180	-11%	-$54.9K	0.01%	535
2022 Q3	$481K	Buy	1,662 +159	+11%	+$45.7K	0.01%	502
2022 Q2	$424K	Buy	1,503 +280	+23%	+$74.9K	0.01%	548
2022 Q1	$319K	Buy	1,223 +20	+2%	+$4.75K	0.01%	653
2021 Q4	$264K	Sell	1,203 -216	-15%	-$42K	﹤0.01%	693
2021 Q3	$257K	Sell	1,419 -200	-12%	-$39K	﹤0.01%	673
2021 Q2	$326K	Buy	1,619 +400	+33%	+$83.7K	0.01%	631
2021 Q1	$262K	Buy	1,219 +200	+20%	+$43.9K	0.01%	648
2020 Q4	$241K	Buy	1,019 +96	+10%	+$22K	﹤0.01%	637
2020 Q3	$251K	Buy	923 +4	+0.4%	+$1.1K	0.01%	599
2020 Q2	$267K	Sell	919 -200	-18%	-$54.2K	0.01%	580
2020 Q1	$266K	Hold	1,119	–	–	0.01%	568
2019 Q4	$245K	Buy	+1,119	New	+$226K	0.01%	639
2019 Q3	–	Sell	-1,100	Closed	-$202K	–	731
2019 Q2	$202K	Hold	1,100	–	–	﹤0.01%	671
2019 Q1	$202K	Buy	+1,100	New	+$203K	﹤0.01%	681
2018 Q4	–	Sell	-1,200	Closed	-$231K	–	718
2018 Q3	$231K	Hold	1,200	–	–	﹤0.01%	651
2018 Q2	$204K	Buy	+1,200	New	+$186K	﹤0.01%	667
2017 Q3	–	Sell	-2,149	Closed	-$277K	–	687
2017 Q2	$277K	Sell	2,149 -1,251	-37%	-$151K	0.01%	584
2017 Q1	$372K	Sell	3,400 -300	-8%	-$26.4K	0.01%	529
2016 Q4	$273K	Buy	3,700 +400	+12%	+$32.5K	0.01%	562
2016 Q3	$288K	Buy	3,300 +700	+27%	+$66.2K	0.01%	547
2016 Q2	$224K	Hold	2,600	–	–	﹤0.01%	585
2016 Q1	$207K	Sell	2,600 -1,426	-35%	-$129K	﹤0.01%	576
2015 Q4	$507K	Sell	4,026 -43	-1%	-$5.19K	0.01%	456
2015 Q3	$424K	Sell	4,069 -81	-2%	-$10.4K	0.01%	475
2015 Q2	$512K	Hold	4,150	–	–	0.01%	468
2015 Q1	$490K	Buy	4,150 +300	+8%	+$35.9K	0.01%	463
2014 Q4	$457K	Sell	3,850 -300	-7%	-$33.8K	0.01%	467
2014 Q3	$466K	Sell	4,150 -300	-7%	-$28.6K	0.01%	469
2014 Q2	$421K	Sell	4,450 -600	-12%	-$42.1K	0.01%	483
2014 Q1	$357K	Sell	5,050 -12,500	-71%	-$990K	0.01%	481
2013 Q4	$1.3M	Sell	17,550 -1,500	-8%	-$104K	0.03%	330
2013 Q3	$1.44M	Buy	19,050 +800	+4%	+$63.7K	0.03%	312
2013 Q2	$1.46M	Buy	+18,250	New	+$1.34M	0.03%	303

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Pinnacle Associates's VRTX Position: Q1 2026 in Review

Pinnacle Associates reduced its Vertex Pharmaceuticals (VRTX) stake by 14% in Q1 2026, selling an estimated $1.7M and leaving 21,590 shares worth $9.64M. The position accounts for 0.12% of the portfolio, ranked #174.

Pinnacle Associates first reported a position in VRTX in Q2 2013 and has held it in 47 quarters since. The position peaked at $12.1M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Pinnacle Associates held 21,590 shares of Vertex Pharmaceuticals worth $9.64M as of Q1 2026.
Pinnacle Associates sold 3,648 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.7M.
Vertex Pharmaceuticals made up 0.12% of Pinnacle Associates's portfolio in Q1 2026, its #174 holding.
Pinnacle Associates first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
Pinnacle Associates's Vertex Pharmaceuticals position peaked at $12.1M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Pinnacle Associates's 13F filing for Q1 2026, filed 22 Apr 2026.